Compare OMAB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMAB | DFTX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.0B |
| IPO Year | 2006 | 2020 |
| Metric | OMAB | DFTX |
|---|---|---|
| Price | $101.58 | $28.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $117.13 | $72.83 |
| AVG Volume (30 Days) | 79.2K | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.75 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $21.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.31 | $14.62 |
| 52 Week High | $134.99 | $49.70 |
| Indicator | OMAB | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 33.49 |
| Support Level | $96.33 | $20.43 |
| Resistance Level | $104.04 | $38.59 |
| Average True Range (ATR) | 2.46 | 1.85 |
| MACD | -0.95 | -0.47 |
| Stochastic Oscillator | 3.44 | 0.90 |
Grupo Aeroportuario del Centro Norte SAB de CV operates, maintains and develops airports in the Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages hotels, industrial parks, and individual airports. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, and in Others.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.